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Abstract
Background: notch receptors are critical determinants
of cell fate in a variety of organisms. notch signaling
is involved in the chondrogenic specification of neural
crest cells. aberrant notch activity has been implicat-
ed  in  numerous  human  diseases  including  cancers;
however its role in chondrogenic tumors has not been
clarified. 
Method: tissue samples from a case of primary chon-
drosarcoma  of  the  maxilla  and  its  recurrent  tumor
were examined immunohistochemically for notch1-4
and  their  ligands  (Jagged1,  Jagged2  and  delta1)  ex-
pression. 
Results:  Both  primary  and  recurrent  tumors  were
histopathologically diagnosed as conventional hyaline
chondrosarcoma  (WHo  grade  I).  Hypercellular  tu-
mor areas strongly expressed notch3 and Jagged1 in
spindle  and  pleomorphic  cells  suggesting  up-regula-
tion of these protein molecules at sites of tumor pro-
liferation. Expression patterns were distinct with some
overlap.  differentiated  malignant  and  atypical  chon-
drocytes  demonstrated  variable  expression  levels  of
Jagged1, and weak to absent staining for notch1, 4
and  delta1.  Protein  immunolocalization  was  largely
membranous  and  cytoplasmic,  sometimes  outlining
the lacunae of malignant chondrocytes. Hyaline carti-
lage demonstrated a diffuse or granular precipitation
of Jagged1 suggesting presence of soluble Jagged1 ac-
tivity  at  sites  of  abnormal  chondrogenesis.  no  im-
munoreactivity for the other notch members was ob-
served. calcified cartilage was consistently notch-neg-
ative indicating down-regulation of notch with carti-
lage  maturation.  Stromal  components  namely  en-
dothelial  cells  and  fibroblasts  variably  expressed
notch1, 3 and Jagged1 but were mildly or non-reactive
for the other members. 
Conclusions:  Results  indicate  that  notch  signaling
pathway may participate in cellular differentiation and
proliferation  in  chondrosarcoma.  findings  implicate
notch3 and Jagged1 as key molecules that influence
the differentiation and maturation of cells of chon-
drogenic lineage.
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IntRoductIon
chondrosarcoma is a rare malignant mesenchymal tu-
mour characterized histopathologically by the produc-
tion of cartilaginous tissue and the absence of pro-
duction of bone tissue by the tumour cells [1-2]. It
ranked as the second most common bone malignancy
where it forms approximately 11% of all primary bone
cancers  [2-3].  chondrosarcoma  mostly  affects  long
bones especially the pelvis, femur and humerus. It is
uncommon in the head and neck region where its fre-
quency of occurrence ranges from 1-12% of all chon-
drosarcomas [3-7]. of these, 10% occur in the jaw-
bones [6,7] and most of these arise in the maxilla with
a predilection for the anterior maxillary region [3-4]. 
chondrosarcomas  are  sub-classified  into  the  con-
ventional (hyaline/myxoid), dedifferentiated, clear cell,
and mesenchymal subtypes [3-5]. conventional chon-
drosarcoma, the most common subtype, is composed
of either hyaline cartilage, myxoid cartilage or a com-
bination of both of these matrices. the hyaline sub-
type is characterized by hypercellular hyaline cartilage
containing  cytologically  atypical  chondrocytes  within
lacunae. In contrast, the atypical chondrocytes of the
myxoid subtype do not reside in lacunae but instead
are enmeshed in a flocculent myxoid matrix. the mes-
enchymal subtype is known to display a more anaplas-
tic appearance. according to the World Health orga-
nization  (WHo)  grading  system,  three  categories  of
chondrosarcoma were identified: grade I (well differ-
entiated),  grade  II  (moderately  differentiated)  and
grade III (poorly differentiated) [1-2]. the biological
behaviour of these tumors is characterized by progres-
sive enlargement and subsequent compression or inva-
sion of local structures such as cranial nerves. com-
plete surgical resection of these tumors is the most ac-
ceptable  treatment  of  choice  [7].  Radiotherapy  and
chemotherapy  as  adjunctive  or  palliative  therapy  re-
main controversial.
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cell proliferation, differentiation, and cell fate in di-
verse tissues [8-11]. Mammalian notch family com-
prises four receptors (notch1, notch2, notch3 and
notch4)  and  five  ligands  (Jagged1,  Jagged2  delta1,
delta2,  delta3  and  delta4).  notch  receptors  are
structurally  homologous  transmembrane  proteins
with distinct differences in their extracellular and in-
tracellular domains (Icd). Jagged (Serrate) and delta
proteins are also structurally related tran membrane
proteins  with  multiple  epidermal  growth  factor
(Egf)-like  repeats  and  dSl  motif  (Delta,  Serrate,
Lag-2) in their extracellular domains [9-11]. Binding
of notch ligands to their receptors on neighboring
cells  induce  proteolytic  cleavages,  releasing  notch
Icd which translocates to the nucleus to interact with
dna-bound proteins. this in turn activates the tran-
scription of selected target genes such as Hes1, Hes5,
and Hes7 [8-11]. dys-regulation of notch signaling
has been implicated in some genetic diseases and tu-
morigenesis [12-13]. aberrant notch can act as either
a tumor promoter or a suppressor depending on the
cell  type  and  context.  Regarding  odontogenic  neo-
plasms, we have reviewed the immunohistochemical
characteristics  of  neoplasms  and  their  physiological
counterparts with notch signaling [14]. In the manu-
script, the data of published literatures suggested that
notch signaling plays some role in cytoplasmic differ-
entiation or acquisition of tissue specific characteris-
tics in neoplastic cells.
It has been demonstrated that markers for notch
signaling  are  differentially  expressed  during  cartilage
development and there is evidence for their functional
role during this process where notch1 is purportedly a
marker for chondrogenic progenitor cells [15-16]. a
search of the English language literature revealed that
although aberrant notch signaling has been detected
in bone malignancies such as an osteosarcoma [17-18]
and odontogenic jaw tumors [19-20], its activity in the
chondrosarcoma  has  not  been  previously  reported.
the aim of this study was to investigate the potential
role of notch signaling during chondroid tumorigene-
sis  by  examining  the  immunolocalization  pattern  of
notch receptors and their ligands in a case of maxil-
lary chondrosarcoma and its recurrent tumor. 
MatERIalS and MEtHodS
tISSuE SaMPlES
formalin-fixed, paraffin-embedded tissue blocks of a
case  of  primary  chondrosarcoma  and  its  recurrence
were retrieved and new 5ﾵm thick sections were pre-
pared for staining with hematoxylin-eosin, and for im-
munohistochemistry.
IMMunoHIStocHEMIStRy
Immunohistochemistrywas performedagainst notch1,
notch2,  notch3,  notch4,  Jagged1,  Jagged2  and
delta1 according to the Envision technique as previ-
ously described [19]. Briefly, deparaffinized sections of
5ﾵm thickness were pretreated for antigen retrieval by
microwaving (99ﾰc) in 10 mM of citrate buffer (pH 6,
20 min). these sections were then immersed in 0.3%
methanol  containing  3%  hydrogen  peroxide  for  20
min, to block endogenous peroxidase, and rinsed in
0.05 M tris-buffered saline (tBS) (5 min, two times)
before immersing in blocking solution (dako corpo-
ration,  ca,  uSa)  for  20  min  at  room  temperature.
then the sections were incubated with the primary an-
tibody  against  each  of  the  notch  family  members
[mouse anti-human notch1 monoclonal antibody (lS-
c16925),  rabbit  anti-human  notch2  polyclonal  anti-
body (lS-B399), rabbit anti-human notch3 polyclonal
antibody (lS-B3399),  rabbit anti-human notch4 poly-
clonal  antibody  (lS-c40785),  lifeSpan  Biosciences
Inc,  Seattle,  Wa,  uSa,  1:500  dilution]  and  ligands
[rabbit anti-human Jagged1 polyclonal antibody (lS-
B2442) and rabbit anti-mouse delta1 polyclonal anti-
body (lS-B72), lifeSpan Biosciences Inc, Seattle, Wa,
uSa, 1:500 dilution], [rabbit anti-human Jagged2 poly-
clonal  antibody  (ab60041),  abcam  Inc,  cambridge,
Ma, uSa, 1:500 dilution], for 1 h at room tempera-
ture. Immunoreactions were performed using the En-
vision Kit (dako corporation, ca, uSa). the anti-
genic  sites  were  visualized  using  diaminobenzidine
(daB) substrate chromogen (dako corporation, ca,
uSa)  and  counterstained  with  Mayer’s  hematoxylin.
for negative control, sections were treated as above
but without the primary antibody. all the control sec-
tions  were  negative.  appropriate  positive  controls
were also applied.
RESultS
HIStologIcal fIndIngS
(fig. 1a)
Microscopic examination of the primary and recurrent
chondrosarcomas  revealed  lesional  tissues  composed
of hypercellular hyaline cartilage containing cytologi-
cally  atypical  chondrocytes  within  lacunae  (fig.  1a).
the histological diagnosis made was conventional or
grade I chondrosarcoma for both the primary and re-
current tumor.
IMMunoHIStocHEMIcal fIndIngS
(fig. 1B-d, 2a-d)
In the hypercellular tumor areas, spindle-shaped and
pleomorphic cells strongly expressed notch3 (fig. 1d)
and  Jagged1  (fig.  2B)  but  were  weakly  positive  for
notch1, notch4 (fig.2a) and weak to non-reactive for
delta1 (fig. 2d). notch2 (fig. 1c) and Jagged2 (fig.
2c) were not detected.
In  the  hyaline  cartilage  areas,  the  malignant  and
atypical  chondrocytes  stained  heterogeneously  for
Jagged1 (fig. 2B), and to a lesser extent notch1 (fig.
1B), notch4 (fig. 2a) and delta1 (fig. 2d). Protein
immunolocalization was largely membranous and cy-
toplasmic, sometimes outlining the lacunae of chon-
drocytes. In addition Jagged1 was also detected as a
diffuse or dotted positivity in the chondroid matrix.
occasional concentric spiral pattern of protein depo-
sition was also observed (fig. 2B). no immunoreactiv-
ity for the other notch members was observed. calci-
fied cartilage was consistently negative for both notch
receptors  and  ligands.  Stromal  components  namely
blood  vessels  and  fibroblasts  stained  variously  for
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Jagged2 and delta1.
dIScuSSIon
the primary chondrosarcoma tumor sample examined
here was from a 58-year-old Malay female who had na-
sopharyngeal carcinoma treated by chemoradiotherapy
about 10 years previously. the recurrent tumor that
developed seven months later was also from the same
patient. Both primary and recurrent tumors were his-
tologically diagnosed as conventional chondrosarcoma
(WHo  grade  I).  although  most  chondrosarcomas
arise de novo, they are common in patients with ol-
lier’s disease, Maffucci syndrome, Paget’s disease and
osteochondroma [1-2]. It is likely that the chondrosar-
coma  that  developed  in  this  patient  is  an  outcome
complication of her treatment. 
Positive immunolocalization of notch receptor and
ligand  protein  in  the  primary  and  recurrent  chon-
drosarcomas  investigated  in  this  study  suggests  that
notch canonical pathway was activated during the de-
velopment of this neoplasm. the expression patterns
of  the  various  notch  members  were  distinct  with
some  overlap.  Strong  expression  for  notch3  and
Jagged1 in the spindle and pleomorphic cells located
in the hypercellular areas of the tumor suggests that
these are key molecules that influenced the cell stem-
ness  of  the  chondrogenic  progenitor  cells.  Reduced
expression  levels  of  Jagged1,  notch1,  notch4  and
delta1 in atypical chondrocytes implies that chondro-
cyte differentiation is associated with downregulation
of these molecules. It has been shown that Jagged1-
mediated  notch  signaling  in  human  bone  marrow
stem cells is necessary to initiate chondrogenesis but
must be switched off for chondrogenesis to proceed
[15].  Similarly, in this study, we observed that Jagged1
was detected in the neoplastic chondroid matrix con-
firming that this molecule is also important as a medi-
ator in notch signaling during oncogenic chondrogen-
esis.  In  addition,  as  with  others  [21],  this  study  too
demonstrates that soluble notch ligands can interact
with  membrane-bound  notch  receptors  to  initiate
proteolysis thus dispelling earlier views that notch sig-
naling  necessitates  interaction  between  membrane-
bound  notch  receptors  and  with  membrane-bound
ligands of adjacent cells.
In summary, a case of primary chondrosarcoma of
the maxilla and its subsequent recurrent tumor were
examined for notch signaling activity. the data from
this case study indicated that this pathway most likely
plays an active and differential role in the acquisition
of tissue-specific characteristics in ythis malignant car-
tilaginous  neoplasm.  current  findings  implicated
notch3 and Jagged1 as key molecules that influence
cell fate decisions in tumoral cells of a chondrogenic
lineage.
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Fig. 1. Photomicrographs of chondrosarcoma showing: a and Inset, lesional areas composed of hyaline cartilage with hypercel-
lular zone at the periphery; B, notch1 moderate expression in atypical chondrocytes; c, notch2 was not detected; d and Inset,
notch3 strong expression in spindle and pleomorphic cells but absence of activity in atypical chondrocytes (original magnifica-
tion, a-d, x400; a, HE staining, a Inset, alcian blue; B, anti-notch1; c, anti-notch2; d and Inset, anti-notch3).
Fig. 2. Photomicrographs of chondrosarcoma showing: a, notch4 weak expression in pleomorphic cells and atypical chondro-
cytes; B, and Inset, Jagged1 strong expression in pleomorphic cells, moderate to weak in atypical chondrocytes; diffuse positivi-
ty of chondroid matrix. note concentric spiral protein deposition; c, Jagged2 was not detected; and d, delta1 weak to absent
expression in spindle and pleomorphic cells and atypical chondrocytes (original magnification, a-d, x400; a, anti-notch4; B
and Inset, anti-Jagged1; c, anti-Jagged2; d, anti-delta1).
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